JAK2 and melanoma: Truncating mutations, homozygous deletions, and low protein levels of IFNGR1, IFNGR2, JAK1, JAK2, STAT1, and IRF1 in melanoma patients result in shorter survival than that of patients with wild-type IFNγ signaling genes [75].